WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H584284
CAS#: 154540-50-8
Description: BT-Sch is a dopamine D1 and D2 receptor-based imaging agent.
Hodoodo Cat#: H584284
Name: BT-Sch
CAS#: 154540-50-8
Chemical Formula: C24H23ClFNOS
Exact Mass: 427.12
Molecular Weight: 427.962
Elemental Analysis: C, 67.36; H, 5.42; Cl, 8.28; F, 4.44; N, 3.27; O, 3.74; S, 7.49
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: BT-Sch
IUPAC/Chemical Name: 7-Chloro-8-hydroxy-1-(4'-(4-fluorobenzyl)thiophenyl)-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
InChi Key: IZYJWVAIDPHRFD-UHFFFAOYSA-N
InChi Code: InChI=1S/C24H23ClFNOS/c1-27-11-10-18-12-23(25)24(28)13-21(18)22(14-27)17-4-8-20(9-5-17)29-15-16-2-6-19(26)7-3-16/h2-9,12-13,22,28H,10-11,14-15H2,1H3
SMILES Code: CN1CC(C2=CC=C(SCC3=CC=C(F)C=C3)C=C2)C4=CC(O)=C(Cl)C=C4CC1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 427.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Gerritz SW, Smith JS, Nanthakumar SS, Uehling DE, Cobb JE. Two general routes to 1,4-disubstituted-2,3,4,5-tetrahydro- 1H-3-benzazepines. Org Lett. 2000 Dec 14;2(25):4099-102. PubMed PMID: 11112653.
2: Gao X, Zhang Y, Wu G. Effects of dopaminergic agents on carrageenan hyperalgesia in rats. Eur J Pharmacol. 2000 Oct 6;406(1):53-8. PubMed PMID: 11011033.
3: Ikemoto S, Glazier BS, Murphy JM, McBride WJ. Role of dopamine D1 and D2 receptors in the nucleus accumbens in mediating reward. J Neurosci. 1997 Nov 1;17(21):8580-7. PubMed PMID: 9334429.
4: Fleckenstein AE, Pögün S, Carroll FI, Kuhar MJ. Recovery of dopamine transporter binding and function after intrastriatal administration of the irreversible inhibitor RTI-76 [3 beta-(3p-chlorophenyl) tropan-2 beta-carboxylic acid p-isothiocyanatophenylethyl ester hydrochloride]. J Pharmacol Exp Ther. 1996 Oct;279(1):200-6. PubMed PMID: 8858994.
5: Ekesbo A, Andrén PE, Gunne LM, Sonesson C, Tedroff J. Motor effects of (-)-OSU6162 in primates with unilateral 6-hydroxydopamine lesions. Eur J Pharmacol. 2000 Feb 18;389(2-3):193-9. PubMed PMID: 10688984.
6: Casas M, Prat G, Rubio A, Barbanoj M, Jané F. Lack of synergism between caffeine and SKF 38393 on rotational behavior in 6-hydroxydopamine-denervated rats. Eur J Pharmacol. 2000 May 19;396(2-3):93-9. PubMed PMID: 10822061.
7: Frau L, Morelli M, Simola N. Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons. Exp Neurol. 2013 Sep;247:663-72. doi: 10.1016/j.expneurol.2013.03.002. Epub 2013 Mar 13. PubMed PMID: 23499830.
8: Hsu KS, Huang CC, Gean PW. Mutual inhibitory effects between dopamine and carbachol on the excitatory synaptic transmission in the rat neostriatum. J Neurosci Res. 1996 Oct 1;46(1):34-41. PubMed PMID: 8892103.
9: Noble F, Cox BM. The role of dopaminergic systems in opioid receptor desensitization in nucleus accumbens and caudate putamen of rat after chronic morphine treatment. J Pharmacol Exp Ther. 1997 Nov;283(2):557-65. PubMed PMID: 9353370.
10: Matthews WD, Sulpizio A, Fowler PJ, DeMarinis R, Hieble JP, Bergamini MV. The ocular hypotensive action of SK&F 86466 in the conscious rabbit. Curr Eye Res. 1984 May;3(5):737-42. PubMed PMID: 6734255.
11: Li KY, Xiao C, Xiong M, Delphin E, Ye JH. Nanomolar propofol stimulates glutamate transmission to dopamine neurons: a possible mechanism of abuse potential? J Pharmacol Exp Ther. 2008 Apr;325(1):165-74. doi: 10.1124/jpet.107.132472. Epub 2008 Jan 23. PubMed PMID: 18216287.
12: Gilliland SL, Alper RH, Levant B. Pharmacology of quinpirole-stimulated [35S]GTPgammaS binding: discrepancy with receptor binding profile. Eur J Pharmacol. 2000 Mar 31;392(3):125-8. PubMed PMID: 10762663.
13: Mach RH, Elder ST, Morton TE, Nowak PA, Evora PH, Scripko JG, Luedtke RR, Unsworth CD, Filtz T, Rao AV, et al. The use of [18F]4-fluorobenzyl iodide (FBI) in PET radiotracer synthesis: model alkylation studies and its application in the design of dopamine D1 and D2 receptor-based imaging agents. Nucl Med Biol. 1993 Aug;20(6):777-94. PubMed PMID: 8401379.
14: Matsumoto M, Yoshioka M, Togashi H, Ikeda T, Saito H. Functional regulation by dopamine receptors of serotonin release from the rat hippocampus: in vivo microdialysis study. Naunyn Schmiedebergs Arch Pharmacol. 1996 May;353(6):621-9. PubMed PMID: 8738295.
15: Piri M, Rostampour M, Nasehi M, Zarrindast MR. Blockade of the dorsal hippocampal dopamine D1 receptors inhibits the scopolamine-induced state-dependent learning in rats. Neuroscience. 2013 Nov 12;252:460-7. doi: 10.1016/j.neuroscience.2013.08.003. Epub 2013 Aug 9. PubMed PMID: 23933216.
16: Tomiyama K, Kato R, Hara Y, Kobayashi M, Mishina M, Yanagawa Y, Kinsella A, Koshikawa N, Waddington JL. Phenotypic characterization of orofacial movement topography in mutants with disruption of amino acid mechanisms: glutamate N2A/B/D [GluRε1/2/4] subtypes and the GABA synthesizing enzyme GAD65. Neuroscience. 2013 Oct 10;250:743-54. doi: 10.1016/j.neuroscience.2013.07.038. Epub 2013 Jul 25. PubMed PMID: 23892010.
17: Abercrombie ED, DeBoer P. Substantia nigra D1 receptors and stimulation of striatal cholinergic interneurons by dopamine: a proposed circuit mechanism. J Neurosci. 1997 Nov 1;17(21):8498-505. PubMed PMID: 9334422.
